Health Trying to Get a COVID-19 Vaccine? These New Tools May Help Written by Brian Mastroianni on April 15, 2021 — Fact checked by Jennifer Chesak Getting an appointment for a COVID-19 vaccine can be a frustrating process, but several tech companies are working to change that. Johner Images/Getty Images Tech companies like Facebook and Google have been promoting new tools to help connect users to vaccination appointments. These tools can not only help people book appointments for a COVID-19 vaccine in their area, they also provide answers to common questions. Some of these tools also include features that allow people to share they got vaccinated and encourage others to do the same. As COVID-19 vaccinations become more accessible to people throughout the United States, what everyone wants to know is, how and where can you make an appointment? Federal and local health departments have established vaccination sites, while major pharmacy chains like CVS and Walgreens have set

Health  Health New Tool Tracks Vaccination and Vaccine Hesitancy Rates Across Geographies, Population Groups Lydia Anderson, Thomas File, Joey Marshall, Kevin McElrath, Zachary Scherer  |  April 14, 2021 Who is getting a COVID-19 vaccine? Who is hesitant about receiving it and why? What state has the highest vaccination or hesitancy rate? The rollout of COVID-19 vaccines has been the subject of extensive news coverage and a new U.S. Census Bureau data visualization tool aims to provide insights into the public’s feelings about COVID-19 vaccines in near real time.

Health Zydus Cadila cuts Remdesivir price to ₹899 Branded as Remdac, it is now more affordable for Covid-19 patients in India Drug major Cadila Healthcare Limited (Zydus Cadila) has revised the price for Remdesivir — branded as Remdac — at ₹899 for 100mg lyophilized injection. RemdacTM was launched in August 2020 at ₹2,800 by Zydus Cadila for Covid-19 patients in India. The prices have been reduced subsequently over the months, and the latest downward revision is further seen benefiting patients in this critical time. The drug today continues to be India’s most economical brand of Remdesivir and a critical drug in the treatment of Covid-19, Zydus said in a statement. Critical drug Sharvil Patel, Managing Director, Cadila Healthcare Limited, said, “Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people. Remdac has been one of the critical drugs in the disease management on Covid and we hope that this price cut will enab

Health NIH experts call for accelerated research to address concurrent HIV and COVID-19 pandemics AddThis Sharing Buttons Share to Print Share to Email Share to Facebook Share to Twitter Share to More   What   The COVID-19 pandemic is affecting people with or at risk for HIV both indirectly, by interfering with HIV treatment and prevention services, and directly, by threatening individual health. An effective response to these dual pandemics requires unprecedented collaboration to accelerate basic and clinical research, as well as implementation science to expeditiously introduce evidence-based strategies into real-world settings. This message comes from a review article co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues published in the Journal of Infectious Diseases. By disrupting critical health care services, the COVID-

Health NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his  announcement  of a new NIH initiative—called UNITE—to end racial inequities in biomedical research. Through UNITE, NIH seeks to better understand stakeholder experiences, improve biomedical research culture and structure, spearhead new research on health disparities, and enhance transparency and communication with internal and external stakeholders. NIDCR Funds Additional COVID-19 Studies Since the start of the pandemic, NIDCR has issued $4.7 million in supplemental funding for basic and clinical studies to understand COVID-19 in the context of denta